Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
|Articles|November 19, 2020
Latest Version of TrialAssure ANONYMIZE Released
Advertisement
TrialAssure has released its latest version of ANONYMIZE for Documents, including the functionality to anonymize and redact PDF documents concurrently.
TrialAssure ANONYMIZE for Documents is a document redaction and anonymization software that combines machine learning—a form of artificial intelligence—and natural language processing to protect patient privacy by automatically finding, masking, anonymizing, or removing personal or company confidential information from unstructured text.
“We are seeing a dramatic increase in the need for clinical trial sponsors to complete new and retrospective anonymization of clinical documents,” said Kelly Vaillant, Director of Global Transparency Strategy & Compliance, TrialAssure. “The impetus for document anonymization comes as increasing regulations from global health authorities and added pressure from advocacy groups push for the expanded utility of data for secondary research.”
To learn more, click
Advertisement
Related to this article
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Embedding AI Across Operations, Faster Trial Decisions, and Voceryq Approval
5